Chris Beaver is a Project Safety Supervisor for Ames based in the Rocky Mountain Regional Office. For the past three years, he has overseen construction safety for heavy civil, highway, transit, and rail projects. His responsibilities include administering Ames' company-wide safety program. He has experience overseeing safety on various projects involving heavy construction, rail lines, and infrastructure work. Chris ensures safety compliance and conducts training to establish a strong safety culture on all projects.
Muhammad Moolla successfully completed training courses in August 2015 on operation, line maintenance, troubleshooting, and heavy maintenance and repair of Rotax 912i series aircraft engines as issued by BRP-Powertrain and Aviation Supplies, with certificates of completion valid from August 2015 through July 2017.
Chris Beaver is a Project Safety Supervisor for Ames based in the Rocky Mountain Regional Office. For the past three years, he has overseen construction safety for heavy civil, highway, transit, and rail projects. His responsibilities include administering Ames' company-wide safety program. He has experience overseeing safety on various projects involving heavy construction, rail lines, and infrastructure work. Chris ensures safety compliance and conducts training to establish a strong safety culture on all projects.
Muhammad Moolla successfully completed training courses in August 2015 on operation, line maintenance, troubleshooting, and heavy maintenance and repair of Rotax 912i series aircraft engines as issued by BRP-Powertrain and Aviation Supplies, with certificates of completion valid from August 2015 through July 2017.
With massive amounts of computational power, machines can now recognize objects and translate speech in real time. Thanks to Deep Learning, Artificial Intelligence is now getting smart. Deep Learning models attempt to mimic the activity of the neocortex. It is understood that the activity of these layers of neurons is what constitutes a brain to be able to "think". These models learn to recognize patterns in digital representations of data in a very similar sense to humans. In this survey report, we introduce the most important concepts of Deep Learning along with the state of the art models that are now widely adopted in commercial products.
Este documento resume la oratoria latina. Define la oratoria como un género literario en prosa que busca convencer, persuadir u conmover al público mediante el discurso hablado. Explica que la oratoria romana evolucionó bajo influencia griega entre los siglos III-II a.C. y destaca figuras como Cicerón, considerado el máximo exponente del género. Finalmente, señala que la oratoria decayó durante el Imperio al perderse la libertad política que la había impulsado.
7 Powerful MENTAL TRIGGERS - convince and influence YOUR customers Mateusz Szumilo
7 Powerful MENTAL TRIGGERS that will help you make a bank!
You suck at Marketing and Selling, a short guide that will turn you from a miserable marketer into a rich entrepreneurs! Give it a try now - motivational social media marketing tips !
15 Statistics to Help Improve Your Sales PerformanceWrike
http://www.wrike.com/blog - As you improve the performance of your sales organization, check out these stats on what works (and what doesn't) when trying to close a deal.
Conférence du Dr. Bruno Roche (Hépatologue, Hôpital Paul Brousse, France). Physiopathologie, Facteurs de risque, incidence et prise en charge de la réactivation virale B après négativation du virus.
Biomarkers can provide non-invasive estimates of liver fibrosis to address the large number of undiagnosed cases. Liver biopsy has limitations as a gold standard due to sampling error and inter-observer variability. New methods show that biopsy has a "gray zone" for intermediate fibrosis stages, while biomarkers like FibroTest have a smaller gray zone and similar diagnostic accuracy to biopsy. Guidelines now recommend the use of validated biomarkers and elastography to diagnose liver fibrosis given biopsy's limitations.
This document discusses the long-term benefits of antiviral treatment for hepatitis B. It provides information on different phases of hepatitis B infection and when treatment is indicated. It also summarizes the approved antiviral drugs for treating chronic hepatitis B, including nucleoside analogs, nucleotide analogs, and cytokines. The document discusses the differences in lifecycles and mechanisms of HIV, HBV, and HCV. It then reviews the efficacy and resistance profiles of different antiviral drugs over time, highlighting the low resistance of tenofovir.
This document discusses treatment of hepatitis B and long-term benefits. It begins by outlining the different phases of hepatitis B infection and when treatment is indicated. The goals of treatment are virological suppression, normalization of liver enzymes, prevention of disease progression, and seroconversion from HBeAg to anti-HBe and from HBsAg to anti-HBs. Approved antiviral drugs for hepatitis B include lamivudine, entecavir, telbivudine, adefovir, tenofovir, interferon alfa, and pegylated interferon alfa-2a. Combination therapies and management of resistance are also discussed.
This document discusses hepatitis C recurrence after liver transplantation. It notes that hepatitis C recurrence is a major issue, accounting for two-thirds of graft loss. Five years post-transplant, 30% of patients have cirrhosis of the graft. The document examines factors that influence recurrence like fibrosis stage and viral load at one year post-transplant. It also discusses using antiviral treatment before and after transplant to improve outcomes.
This document discusses optimal strategies for preventing hepatitis B virus (HBV) recurrence after liver transplantation. It reviews evidence that combination prophylaxis with hepatitis B immunoglobulin (HBIG) and nucleoside/nucleotide analogues (NUCs) is most effective at preventing early HBV reinfection. For long-term prophylaxis, low-dose HBIG or HBIG discontinuation combined with lifelong NUC therapy may be sufficient for patients at low risk of recurrence. Factors such as HBV DNA level pre-transplant, hepatocellular carcinoma, and HBV/HIV coinfection increase risk of recurrence and require continued HBIG plus NUC prophylaxis.
The document discusses hepatitis C virus (HCV) resistance to direct-acting antiviral (DAA) drugs. It finds that:
1) Baseline resistance-associated variants (RAVs) were detected in 15-27% of treatment-naive genotype 1 patients by deep sequencing, with higher prevalences in some regions.
2) The presence of certain RAVs at baseline was associated with reduced sustained virologic response (SVR) rates to some DAA regimens, particularly for NS5A inhibitors.
3) However, most patients with baseline RAVs still achieved SVR when treated with optimized, interferon-free combinations with or without ribavirin extension.
32. Etude Cas-Témoins Lamivudine en Prévention de la Réactivation B après Greffe de Moelle Hépatite par réactivation virale B Préventive par Lamivudine (n=20) Pas de Prévention (n=20) 5% (1/20) 45% (9/20) Délai réactivation (moy, j) 117 252 Lau Hepatology, 2002
33. Prévention par la Lamivudine de la Réactivation B après Greffe de Moelle Lau Hepatology, 2002 Lamivudine: seul fact indépendant de l’absence de réactivation B 94% 54% 1 an
34. Prévention de la réactivation B en hémato-oncologie Lalazar Br J Hematol 2007